Tech Company Financing Transactions
NeoPhore Funding Round
NeoPhore, based in Cheshire, scored funding from Bristol Myers Squibb.
Transaction Overview
Company Name
Announced On
5/22/2024
Transaction Type
Venture Equity
Amount
Unknown
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to explore novel biology associated with the DNA mismatch repair ('MMR') pathway in cancer, as well as further progress its pre-clinical studies and deliver a candidate drug in 2025.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3rd Floor, 1 Ashley Road, Altrincham
Cheshire, WA14 2DT
UK
Cheshire, WA14 2DT
UK
Phone
Website
Email Address
Overview
Our approach targets the dynamics of cancer neoantigen evolution through the discovery and design of effective, well-tolerated medicines that will become a key part of the next-generation of cancer immunotherapies. Our compounds target components of the MMR pathway that have been validated in both clinical and preclinical studies. These components are known to modulate neoantigen creation and diversity across numerous cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Matthew Baker
Chief Financial Officer
Stephen Over
Chief Scientific Officer
Martin Drysdale
Browse more venture capital transactions:
Prev: 5/22/2024: Aerodome venture capital transaction
Next: 5/22/2024: Amino Health venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs